SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives
Holly E Gurgle, Karen White, Carrie McAdam-Marx Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, USA Abstract: Controversy exists regarding the selection of second-line therapy for patients with type 2 diabetes mellitus (T2DM) who are unabl...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-06-01
|
| Series: | Vascular Health and Risk Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/sglt2-inhibitors-or-glp-1-receptor-agonists-as-second-line-therapy-in--peer-reviewed-article-VHRM |
| _version_ | 1818497824408469504 |
|---|---|
| author | Gurgle HE White K McAdam-Marx C |
| author_facet | Gurgle HE White K McAdam-Marx C |
| author_sort | Gurgle HE |
| collection | DOAJ |
| description | Holly E Gurgle, Karen White, Carrie McAdam-Marx Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, USA Abstract: Controversy exists regarding the selection of second-line therapy for patients with type 2 diabetes mellitus (T2DM) who are unable to achieve glycemic control with metformin therapy alone. Newer pharmacologic treatments for T2DM include glucagon-like peptide-1 receptor agonists and sodium–glucose cotransporter 2 inhibitors. Both the classes of medication are efficacious, exhibit positive effects on weight, and are associated with minimal risk of hypoglycemia. The purpose of this review is to compare the clinical trial and real-world effectiveness data of glucagon-like peptide-1 receptor agonists versus sodium–glucose cotransporter 2 inhibitors related to A1c reduction, weight loss, cost-effectiveness, cardiovascular outcomes, and safety in patients with T2DM. This review summarizes comparative evidence for providers who are determining which of the two classes may be the most appropriate for a specific patient. Keywords: type 2 diabetes mellitus, GLP-1 receptor agonist, SGLT2 inhibitor, A1c, weight loss, adverse effect |
| first_indexed | 2024-12-10T18:50:12Z |
| format | Article |
| id | doaj.art-b3c1e5293000488199bfba4bb573c1ef |
| institution | Directory Open Access Journal |
| issn | 1178-2048 |
| language | English |
| last_indexed | 2024-12-10T18:50:12Z |
| publishDate | 2016-06-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Vascular Health and Risk Management |
| spelling | doaj.art-b3c1e5293000488199bfba4bb573c1ef2022-12-22T01:37:20ZengDove Medical PressVascular Health and Risk Management1178-20482016-06-012016Issue 123924927288SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectivesGurgle HEWhite KMcAdam-Marx CHolly E Gurgle, Karen White, Carrie McAdam-Marx Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, USA Abstract: Controversy exists regarding the selection of second-line therapy for patients with type 2 diabetes mellitus (T2DM) who are unable to achieve glycemic control with metformin therapy alone. Newer pharmacologic treatments for T2DM include glucagon-like peptide-1 receptor agonists and sodium–glucose cotransporter 2 inhibitors. Both the classes of medication are efficacious, exhibit positive effects on weight, and are associated with minimal risk of hypoglycemia. The purpose of this review is to compare the clinical trial and real-world effectiveness data of glucagon-like peptide-1 receptor agonists versus sodium–glucose cotransporter 2 inhibitors related to A1c reduction, weight loss, cost-effectiveness, cardiovascular outcomes, and safety in patients with T2DM. This review summarizes comparative evidence for providers who are determining which of the two classes may be the most appropriate for a specific patient. Keywords: type 2 diabetes mellitus, GLP-1 receptor agonist, SGLT2 inhibitor, A1c, weight loss, adverse effecthttps://www.dovepress.com/sglt2-inhibitors-or-glp-1-receptor-agonists-as-second-line-therapy-in--peer-reviewed-article-VHRMtype 2 diabetes mellitusGLP-1 receptor antagonistSGLT2 inhibitorA1cweight lossadverse effect |
| spellingShingle | Gurgle HE White K McAdam-Marx C SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives Vascular Health and Risk Management type 2 diabetes mellitus GLP-1 receptor antagonist SGLT2 inhibitor A1c weight loss adverse effect |
| title | SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives |
| title_full | SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives |
| title_fullStr | SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives |
| title_full_unstemmed | SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives |
| title_short | SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives |
| title_sort | sglt2 inhibitors or glp 1 receptor agonists as second line therapy in type 2 diabetes patient selection and perspectives |
| topic | type 2 diabetes mellitus GLP-1 receptor antagonist SGLT2 inhibitor A1c weight loss adverse effect |
| url | https://www.dovepress.com/sglt2-inhibitors-or-glp-1-receptor-agonists-as-second-line-therapy-in--peer-reviewed-article-VHRM |
| work_keys_str_mv | AT gurglehe sglt2inhibitorsorglp1receptoragonistsassecondlinetherapyintype2diabetespatientselectionandperspectives AT whitek sglt2inhibitorsorglp1receptoragonistsassecondlinetherapyintype2diabetespatientselectionandperspectives AT mcadammarxc sglt2inhibitorsorglp1receptoragonistsassecondlinetherapyintype2diabetespatientselectionandperspectives |